This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Solid tumors	EPH receptor A3 (EPHA3)	<p><i>In vitro</i> and mouse studies suggest EPHA3 antibodies could help treat solid tumors. In tissue samples from patients with cancer, EPHA3 was expressed in the tumor stroma and vasculature but not in organ-matched healthy tissue. In mice, a chimeric version of the EPHA3 antibody KB004 inhibited growth of EPHA3⁺ and EPHA3⁻ cancer xenografts by disrupting the stroma and tumor microvessel architecture. Next steps could include testing the antibody in additional animal models of solid tumors.</p> <p>KaloBios Pharmaceuticals Inc. has KB004 in Phase II testing to treat hematologic malignancies.</p> <p>SciBX 7(36); doi:10.1038/scibx.2014.1069 Published online Sept. 18, 2014</p>	Patent and licensing status unavailable	<p>Vail, M.E. <i>et al. Cancer Res.</i>; published online Aug. 15, 2014; doi:10.1158/0008-5472.CAN-14-0218</p> <p>Contact: Mary E. Vail, Monash University, Clayton, Victoria, Australia e-mail: mary.vail@monash.edu</p>